MedTrace Logo

Effect of Bosentan on Endothelial Function in Patients With Type 2 Diabetes

NCT01357109 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 56

Last updated 2011-05-20

No results posted yet for this study

Summary

The purpose of the study is to investigate if oral treatment with bosentan improves endothelium-dependent vasodilatation in patients with type 2 diabetes and microangiopathy.

Conditions

Interventions

DRUG

Bosentan

62.5 mg bid for two weeks and 125 mg bid for two weeks

DRUG

Placebo

Matched placebo bid

Sponsors & Collaborators

  • Swedish Heart Lung Foundation

    collaborator OTHER

  • The Swedish Research Council

    collaborator OTHER_GOV

  • Actelion

    collaborator INDUSTRY

  • Karolinska Institutet

    lead OTHER

Principal Investigators

  • John Pernow, Dr · Karolinska Institutet

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-11-30
Primary Completion
2010-04-30
Completion
2011-01-31

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01357109 on ClinicalTrials.gov